for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Top News

Breakingviews: M&A lacking Elan

Posted

Feb 25 - Royalty Pharma's $6.6 bln approach for the biotech is at a scrawny 4 percent premium. Richard Beales and Robert Cyran discuss why the specialist investor may still be the right owner – at the right price.

Top News

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up